21829-25-4 Nifedipine AKSci J10593
 
 
Loading Please Wait...
  J10593    AKSci Reference Standard
Nifedipine
, 99% (HPLC)
 
1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester




IDENTITY
CAS Number:21829-25-4
MDL Number:MFCD00057326
MF:C17H18N2O6
MW:346.33
EINECS:244-598-3
SPECIFICATIONS & PROPERTIES
Purity:99% (HPLC)
Spectra:FT-IR, LCMS, HPLC
Physical Form:Off-white to yellow powder
Melting Point:171-176°C
Long-Term Storage:Store long-term at 2-8°C

BIOLOGICAL INFO
Solubility:DMSO; EtOH
Application(s):Vasodilator agent

REVIEW

 Nifedipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure.

REFERENCES
[1]Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72.
[2] Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54.
[3] Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8.
[4] Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H302

Precautionary Statements
P264; P270; P301+P312; P330; P501


Current as of March 26, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

CATEGORIES

 APIs and Bioactives > Calcium Channel Blockers


PubChem